A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole

A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women

A single dose trial to evaluate the pharmacokinetics of testosterone and anastrozole from subcutaneous testosterone and anastrozole (T+Ai) in premenopausal women

Study Overview

• Status: Completed
• Conditions: Mammographic Density
• Intervention / Treatment: Drug: testosterone anastrozole

Detailed Description

The trial is of open label single centre design. The serum concentrations of testosterone and plasma concentrations of anastrozole will be measured in 12 premenopausal women. Participants will be stratified in a 50:50 manner in two BMI (Body Mass Index) groups, <25 and 25 kg/m2, respectively. There will be a lead group of two participants in whom the serum/plasma concentrations will be examined after the first four weeks, to determine whether the sampling schedule adequately describes the serum/plasma concentration-time profiles or should be adjusted.

• Study Type: Interventional
• Enrollment (Actual): 11
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • South Australia
    • Toorak Gardens, South Australia, Australia, 5065
      • Wellend Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Agree to and be capable of understanding and signing an Informed Consent Form.
2. Patients seeking treatment with Investigational Product for the reduction in high mammographic breast density (MBD).
3. Pre-menopausal levels of Follicular stimulating hormone/Leutinizing hormone/estradiol(follicle stimulating hormone/luteinizing hormone/oestrogen) according to the definition of "pre-menopausal range" for the laboratory involved.
4. Volpara Density volumetric breast density of ≥15.5% (combined average both breasts)
5. Age between 35-55 years inclusive.
6. Body weight between 50-90 kg inclusive.
7. BMI between 20-30 kg/m2 inclusive.
8. Good venous access for venepuncture.
9. In good general health without clinically significant cardiac, respiratory, or psychiatric disease.
10. Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilisation), no more than seven days before the first dose of Investigational Product.
11. For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception (Mirena (TM) allowed) during and for at least six months after completion of treatment with Investigational Product; OR, a fertile male partner willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilisation) during and for at least six months after completed dosing Investigational Product.

Exclusion Criteria:

1. Presence of breast cancer.
2. Previous or concomitant other malignancy (non-breast, other than skin) within the previous five years.
3. Diabetes mellitus or glucose intolerance defined as a fasting glucose of ≥ 6 mmol/L.
4. History of coronary artery disease.
5. Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected blood.
6. Existing testosterone, oestrogen and/or anastrozole treatment.
7. Concomitant medication which induces or inhibits CYP3A4 (Listed in Appendix A).
8. Current warfarin usage.
9. Prolonged systemic corticosteroid treatment, inhalation and topical steroids allowed.
10. Known hypersensitivity to any component of Investigational Product.
11. Systemic reproductive hormone replacement therapy.
12. Systemic hormonal contraception.
13. Participation in another clinical trial of an Investigational Product within 30 days of entry into the present trial or within 4-5 half-lives of the Investigational Product, whichever is the longer.
14. Use of any product containing ginseng within 30 days of screening.
15. Pregnant or lactating women.
16. Unable to comply with trial requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: testosterone anastrozole implant; testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet	Drug: testosterone anastrozole; subcutaneous testosterone and anastrozole; Other Names: testosterone; anastrozole

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
testosterone Cmax	Peak Plasma Concentration	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
testosterone AUC	Area under the plasma concentration versus time curve	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
testosterone T1/2	plasma half-life	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
anastrozole Cmax	Peak Plasma Concentration	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
anastrozole AUC	Area under the plasma concentration versus time curve	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
anastrozole T1/2	plasma half-life	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	To assess the safety and tolerability of T+Ai following a single dose of T+Ai by subcutaneous implantation. Biochemical and hematological will be evaluated and the number of participants with abnormal values or adverse events that are related to treatment will be recorded	The outcome measures will be reported weekly until study completion-3 months
dihydrotestosterone metabolism	To description of the time course of dihydrotestosterone serum concentrations.	3 months
breast elasticity	Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85. A Supersonic Ultrasound will be carried out by four quadrant analysis of each breast with 6x3mm Q box analyses measured in kPa.	Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85

Collaborators and Investigators

• Sponsor: Havah Therapeutics Pty Ltd
• Investigators: Principal Investigator: Stephen N Birrell, Md PhD, Wellend Health

Study record dates

Study Major Dates

• Study Start (Actual): August 14, 2017
• Primary Completion (Actual): April 17, 2018
• Study Completion (Actual): April 17, 2018

Study Registration Dates

• First Submitted: August 6, 2017
• First Submitted That Met QC Criteria: October 17, 2017
• First Posted (Actual): October 19, 2017

Study Record Updates

• Last Update Posted (Actual): April 18, 2018
• Last Update Submitted That Met QC Criteria: April 17, 2018
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Androgens; Anabolic Agents; Testosterone; Anastrozole; Methyltestosterone; Testosterone undecanoate; Testosterone enanthate; Testosterone 17 beta-cypionate
• Other Study ID Numbers: HAV-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No